A Phase 1, Single-Center, Open-Label, 2-Arm Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 mg and 60 mg Delayed-Release Capsules in Healthy Chinese Subjects

Trial Profile

A Phase 1, Single-Center, Open-Label, 2-Arm Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 mg and 60 mg Delayed-Release Capsules in Healthy Chinese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Erosive oesophagitis; Gastro-oesophageal reflux; Gastrointestinal disorders
  • Focus Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 08 Feb 2018 Status changed from recruiting to completed.
    • 22 Jan 2018 Planned End Date changed from 9 Jan 2018 to 30 Jan 2018.
    • 22 Jan 2018 Planned primary completion date changed from 28 Dec 2017 to 26 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top